Dr. Nathan Boggs developed an international clinical registry for Tricare beneficiaries known, or suspected to have, the myeloid neoplasm systemic mastocytosis. The registry is designed to reduce the time to diagnosis and improve the care of those who are diagnosed. Dr. Boggs has developed clinical and research collaborations with ARUP labs and the National Institutes of Health (NIH) Clinical Center and helped Walter Reed obtain a Center of Excellence designation by the American Initiative in Mast Cell Diseases (AIM).

Dr. Boggs is principal investigator (PI) of multiple funded research studies. One study, in collaboration with Drs. Clifton Dalgard and Andrew Snow at USU, aims to improve genetic diagnosis rates compared to standard of care genetic testing for patients with inborn errors of immunity and mastocytosis. The study utilizes a whole genome and RNA sequencing approach. A second study is assessing the genetic underpinning of urticaria. Dr. Boggs it also the Walter Reed site PI for the SUMMIT clinical trial investigating bezuclastinib for non-advanced systemic mastocytosis.